Studies on the modification of low-dose hyper-radiosensitivity in prostate cancer cells by incubation with genistein and estradiol-7

Oma cell line that expresses both ER-α and ER-β, whereas BG-1 is an ovarian cell that does not express these receptors. Expression of the receptors reflects a brown staining. For easier analysis, staining of the nuclei with DAB was not performed in the presented samples of LNCaP and PC-3. While LNCaP cells showed expression of ER-α and ER-β, PC-3 cells did not.<p><b>Copyright information:</b></p><p>Taken from "studies on the modification of low-dose hyper-radiosensitivity in prostate cancer cells by incubation with genistein and estradiol"</p><p>http://www.ro-journal.com/content/3/1/19</p><p>Radiation Oncology (London, England) 2008;3():19-19.</p><p>Published online 14 Jul 2008</p><p>PMCID:PMC2490684.</p><p></p

Studies on the modification of low-dose hyper-radiosensitivity in prostate cancer cells by incubation with genistein and estradiol-5

. In controls incubated in FCS containing media and in controls incubated in media with FCS-withdrawal there was a induction of p21 expression. The same was seen in cells after incubation with low doses of estradiol (0.01 μM) and genistein (0.01 μM). After incubation with high concentrations of estradiol (10 μM) and genistein (10 μM) the induction of p21 was completely abolished.<p><b>Copyright information:</b></p><p>Taken from "studies on the modification of low-dose hyper-radiosensitivity in prostate cancer cells by incubation with genistein and estradiol"</p><p>http://www.ro-journal.com/content/3/1/19</p><p>Radiation Oncology (London, England) 2008;3():19-19.</p><p>Published online 14 Jul 2008</p><p>PMCID:PMC2490684.</p><p></p

Studies on the modification of low-dose hyper-radiosensitivity in prostate cancer cells by incubation with genistein and estradiol-4

To fit the low-dose hyper-radiosensitivity region of the control curves while the genistein and estradiol curves followed a linear-quadratic equation. Incubation with genistein and estradiol abolished the HRS to low irradiation doses seen in the controls (genistein 10 μM vs. controls: 0.4 Gy: p < 0.01; 0.6 Gy: p = 0.027; estradiol 10 μM vs. controls: 0.4 Gy: p < 0.001; 0.6 Gy: p < 0.001). At and above 2 Gy there were no significant differences between the surviving clones after hormonal incubation and controls.<p><b>Copyright information:</b></p><p>Taken from "studies on the modification of low-dose hyper-radiosensitivity in prostate cancer cells by incubation with genistein and estradiol"</p><p>http://www.ro-journal.com/content/3/1/19</p><p>Radiation Oncology (London, England) 2008;3():19-19.</p><p>Published online 14 Jul 2008</p><p>PMCID:PMC2490684.</p><p></p

Studies on the modification of low-dose hyper-radiosensitivity in prostate cancer cells by incubation with genistein and estradiol-2

Increased colony formation significantly (LNCaP: p < 0.0001; PC-3: p < 0.0001), while higher concentrations of estradiol did not influence colony formation in comparison to untreated controls.<p><b>Copyright information:</b></p><p>Taken from "studies on the modification of low-dose hyper-radiosensitivity in prostate cancer cells by incubation with genistein and estradiol"</p><p>http://www.ro-journal.com/content/3/1/19</p><p>Radiation Oncology (London, England) 2008;3():19-19.</p><p>Published online 14 Jul 2008</p><p>PMCID:PMC2490684.</p><p></p

Studies on the modification of low-dose hyper-radiosensitivity in prostate cancer cells by incubation with genistein and estradiol-1

Tion in colony forming is observed after incubation with genistein. Colony formation was reduced to 50% of the controls in LNCaP afer incubation with genistein 0.01 μM (p = 0.004). Higher genistein concentrations (0.1 μM and 10 μM) did not further suppress clonogenic survival. In PC-3 incubation with genistein 0.1 μM decreased colony formation to 75% of the controls (p = 0.027), higher concentrations reduced clonogenic survival further (10 μM: p < 0.001; 25 μM: p < 0.001).<p><b>Copyright information:</b></p><p>Taken from "studies on the modification of low-dose hyper-radiosensitivity in prostate cancer cells by incubation with genistein and estradiol"</p><p>http://www.ro-journal.com/content/3/1/19</p><p>Radiation Oncology (London, England) 2008;3():19-19.</p><p>Published online 14 Jul 2008</p><p>PMCID:PMC2490684.</p><p></p

Studies on the modification of low-dose hyper-radiosensitivity in prostate cancer cells by incubation with genistein and estradiol-3

To fit the low-dose hyper-radiosensitivity region of all curves. Incubation with genistein 10 μM and estradiol 10 μM enlarged the area of radiohypersensitivity to doses of up to 1 Gy when compared to untreated controls. p-values for LNCaP control vs. genistein 10 μM were p < 0.05 at the following dose points: 0.4 Gy, 0.5 Gy, 0.6 Gy, 0.8 Gy, 1 Gy. No significant differences were found between the clonogenic survival curves at 0 Gy, 0.2 Gy, 2 Gy, 3 Gy and 4 Gy. p-values for LNCaP controls vs. estradiol 10 μM were p < 0.05 at the following dose points: 0.4 Gy, 0.6 Gy, 0.8 Gy, 1 Gy and 3 Gy. No significant differences were found at 0 Gy, 0.5 Gy, 2 Gy and 4 Gy.<p><b>Copyright information:</b></p><p>Taken from "studies on the modification of low-dose hyper-radiosensitivity in prostate cancer cells by incubation with genistein and estradiol"</p><p>http://www.ro-journal.com/content/3/1/19</p><p>Radiation Oncology (London, England) 2008;3():19-19.</p><p>Published online 14 Jul 2008</p><p>PMCID:PMC2490684.</p><p></p

Studies on the modification of low-dose hyper-radiosensitivity in prostate cancer cells by incubation with genistein and estradiol-0

Oma cell line that expresses both ER-α and ER-β, whereas BG-1 is an ovarian cell that does not express these receptors. Expression of the receptors reflects a brown staining. For easier analysis, staining of the nuclei with DAB was not performed in the presented samples of LNCaP and PC-3. While LNCaP cells showed expression of ER-α and ER-β, PC-3 cells did not.<p><b>Copyright information:</b></p><p>Taken from "studies on the modification of low-dose hyper-radiosensitivity in prostate cancer cells by incubation with genistein and estradiol"</p><p>http://www.ro-journal.com/content/3/1/19</p><p>Radiation Oncology (London, England) 2008;3():19-19.</p><p>Published online 14 Jul 2008</p><p>PMCID:PMC2490684.</p><p></p

Studies on the modification of low-dose hyper-radiosensitivity in prostate cancer cells by incubation with genistein and estradiol-6

Ignated probes were irradiated with 4 Gy. In the following time, every 6 h probes were stained with DAPI and analyzed in a flow cytometer up to point "72 h". Every result reflects 3 independent assays. Proportion of cells in G0/G1 is symbolised by a bar, G2/M by a white bar and S-phase by a black bar. In the controls 15% of the cells were in S-phase, 65% in G0/G1 and 20% in G2/M. In the following, the S-phase was reduced to 5%, while G0/G1 increased to 73%. The proportion of cells in G2/M showed minimal changes. After incubation with genistein 10 μM no significant differences when compared to untreated controls were observed. After irradiation with 4 Gy the proportion of cells in G0/G1 decreased from 73% to 62%, in S-phase decreased from 8% to 3.6% and in G2/M phase increased from 21% to 34.3%. Similar results were observed after incubation with genistein 10 μM and irradiation with 4 Gy. In the controls 15% of the cells were in S-phase, 65% in G0/G1 and 20% in G2/M. In the following, the S-phase was reduced to 5%, while G0/G1 increased to 73%. The proportion of cells in G2/M was only minimal changes. After incubation with genistein 10 μM no significant differences when compared to untreated controls were observed. After irradiation with 4 Gy the proportion of cells in G0/G1 decreased from 73% to 62%, in S-phase decreased from 8% to 3.6% and in G2/M phase increased from 21% to 34.3%. Similar results were observed after incubation with genistein 10 μM and irradiation with 4 Gy.<p><b>Copyright information:</b></p><p>Taken from "studies on the modification of low-dose hyper-radiosensitivity in prostate cancer cells by incubation with genistein and estradiol"</p><p>http://www.ro-journal.com/content/3/1/19</p><p>Radiation Oncology (London, England) 2008;3():19-19.</p><p>Published online 14 Jul 2008</p><p>PMCID:PMC2490684.</p><p></p

Mutation Analysis of <em>BRCA1, BRCA2, PALB2</em> and <em>BRD7</em> in a Hospital-Based Series of German Patients with Triple-Negative Breast Cancer

<div><p>Triple-negative breast cancer (TNBC) is an aggressive form of breast carcinoma with a poor prognosis. Recent evidence suggests that some patients with TNBC harbour germ-line mutations in DNA repair genes which may render their tumours susceptible to novel therapies such as treatment with PARP inhibitors. In the present study, we have investigated a hospital-based series of 40 German patients with TNBC for the presence of germ-line mutations in <em>BRCA1</em>, <em>BRCA2</em>, <em>PALB2</em>, and <em>BRD7</em> genes. Microfluidic array PCR and next-generation sequencing was used for <em>BRCA1</em> and <em>BRCA2</em> analysis while conventional high-resolution melting and Sanger sequencing was applied to study the coding regions of <em>PALB2</em> and <em>BRD7</em>, respectively. Truncating mutations in <em>BRCA1</em> were found in six patients, and truncating mutations in <em>BRCA2</em> and <em>PALB2</em> were detected in one patient each, whereas no truncating mutation was identified in <em>BRD7</em>. One patient was a double heterozygote for the <em>PALB2</em> mutation, c.758insT, and a <em>BRCA1</em> mutation, c.927delA. Our results confirm in a hospital-based setting that a substantial proportion of German TNBC patients (17.5%) harbour germ-line mutations in genes involved in homology-directed DNA repair, with a preponderance of <em>BRCA1</em> mutations. Triple-negative breast cancer should be considered as an additional criterion for future genetic counselling and diagnostic sequencing.</p> </div

No supra-additive effects of goserelin and radiotherapy on clonogenic survival of prostate carcinoma cells -0

<p><b>Copyright information:</b></p><p>Taken from "No supra-additive effects of goserelin and radiotherapy on clonogenic survival of prostate carcinoma cells "</p><p>http://www.ro-journal.com/content/2/1/31</p><p>Radiation Oncology (London, England) 2007;2():31-31.</p><p>Published online 26 Aug 2007</p><p>PMCID:PMC2034383.</p><p></p>ession of LHRH-receptors